Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
0(0%)
Results Posted
43%(3 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_2
3
27%
Ph phase_1
8
73%

Phase Distribution

8

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
3(27.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(4)

Detailed Status

Completed7
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
63.6%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (72.7%)
Phase 23 (27.3%)

Trials by Status

completed764%
terminated436%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_2

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT05097989
terminatedphase_1

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085
terminatedphase_2

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096
terminatedphase_2

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

NCT04170023
completedphase_1

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05097989Phase 2

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Terminated
NCT05259085Phase 1

Study of ALXN2050 in Participants With Hepatic Impairment

Terminated
NCT05218096Phase 2

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Terminated
NCT04170023Phase 2

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Terminated
NCT04623710Phase 1

Study of ALXN2050 in Participants With Renal Impairment

Completed
NCT05202145Phase 1

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Completed
NCT04952545Phase 1

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Completed
NCT04933682Phase 1

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Completed
NCT04660890Phase 1

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Completed
NCT05047484Phase 1

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Completed
NCT05047458Phase 1

A Study of Single-dose ALXN2050 in Healthy Adults

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11